Marshall Wace
REGN icon

Marshall Wace’s Regeneron Pharmaceuticals REGN Stock Holding History

Marshall Wace’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-800
Closed -$450K – 3397
2025
Q3 		$450K Buy
+800
New +$452K ﹤0.01% 2270
2021
Q4 		– Sell
-2,300
Closed -$1.39M – 4216
2021
Q3 		$1.39M Buy
+2,300
New +$1.43M 0.01% 1797

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Marshall Wace's REGN Position: Q1 2026 in Review

Marshall Wace reduced its Regeneron Pharmaceuticals (REGN) stake by 100% in Q1 2026, selling an estimated $366M and leaving 353 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #2680.

Marshall Wace first reported a position in REGN in Q2 2014 and has held it in 37 quarters since. The position peaked at $369M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Marshall Wace held 353 shares of Regeneron Pharmaceuticals worth $273K as of Q1 2026.
  • Marshall Wace sold 478,198 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $366M.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2680 holding.
  • Marshall Wace first reported a position in Regeneron Pharmaceuticals in Q2 2014 and has held it in 37 quarters since.
  • Marshall Wace's Regeneron Pharmaceuticals position peaked at $369M in Q4 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.